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New Twist on cell migration
I
nstead of packing the dishes and submitting a change of 
address form, a cell that is about to move replaces its 
surface proteins, revamps its cytoskeleton, and alters its 
shape. Lander et al. show that one enzyme serves as a master 
controller for this process.
A cell’s pre-move preparations are referred to as the 
epithelial–mesenchymal transition (EMT). Embryonic cells 
undergo EMT before they relocate during develoment, as do 
tumor cells that are about to metastasize. Researchers are still 
working out how cells regulate EMT so that the molecular 
and behavioral changes occur in concert and at the right time. 
Thus far, they have shown that the transcription factors Slug, 
Snail, Twist, and Sip1 help activate EMT. In turn, the enzyme 
Partner of paired (Ppa) adjusts the levels of Slug and Snail, 
triggering their ubiquitination so that they can be destroyed 
by the proteasome.
Lander et al. discovered that Ppa also controls cellular 
quantities of Twist and Sip1 by promoting their ubiquitination. 
Thus Ppa regulates all four of the EMT-triggering transcription 
factors, despite their structural differences. Using the same 
protein to manage Slug, Snail, Twist, and Sip1 may ensure that 
the transcription factors work in synchrony and that their effects 
can be shut down simultaneously. The work also suggests that 
it might be possible to curtail metastasis by targeting Ppa to 
disrupt EMT.
Lander, R., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201012085.
Bak activators get in the groove
T
he protein Bak be-
longs to a molecular 
hit squad that spurs 
apoptosis. Dai et al. reveal 
that Bak has to make the 
right connection before it 
can kill cells.
Bak and its cousin 
Bax dispatch their victims 
by perforating the outer 
membrane of mitochondria, 
permitting cytochrome c to 
escape. Researchers think 
that a family of proteins 
called BH3-only proteins control this function of Bak and Bax. 
The leading hypothesis is that some BH3-only proteins, known 
as direct activators, bind to Bak or Bax and induce them to oligo-
merize, thereby switching them on. Another group of BH3-only 
proteins, the sensitizers, latch onto antiapoptotic relatives of 
Bak and Bax and prevent them from inhibiting activation.
To nail down the details of Bak’s activation, Dai et al. fol-
lowed its interactions with BH3-only proteins in vitro. They 
found that the protein bound to three direct activators but not 
to one of the sensitizers. Unlike Bax, which loiters in the cyto-
plasm until it’s needed on the mitochondrion, Bak remains on 
the mitochondrial membrane. The researchers showed that a 
lipid milieu wasn’t necessary for binding between BH3-only 
proteins and Bak, although it did strengthen the link between 
the partners.
The researchers also showed that only a transient interaction 
between BH3-only proteins and a groove on Bak was required to 
trigger Bak’s oligomerization. Bak couldn’t kill cells if the team 
prevented this brief interaction. Scientists still need to determine 
the structures of the Bak and Bax oligomers and how they enable 
the proteins to puncture the mitochondrial membrane.
Dai, H., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201102027.
A model shows how a portion of 
the activator Noxa (yellow) settles 
into the groove on Bak.
SUMO defeats protein aggregates
S
umoylation might 
prevent the protein 
aggregations that typ-
ify Parkinson’s disease (PD), 
Krumova et al. report.
Insoluble protein clus-
ters are the hallmarks of several 
neurodegenerative diseases. In 
PD, neurons harbor clumps of 
the protein -synuclein. What 
triggers these protein pileups remains obscure. A possible clue for 
PD came when researchers overexpressed -synuclein in human 
kidney cells and found that the protein was modifi  ed by the addition 
of the small, ubiquitin-like molecule SUMO. Since sumoylation 
generally boosts the solubility of proteins, the result raised the pos-
sibility that SUMO proteins affect the aggregation of -synuclein.
Krumova et al. tested whether sumoylating purified 
-synuclein hindered it from clustering into fibrils, filaments 
similar to those detected in neurons of PD patients. If all of 
the -synuclein molecules in a solution were sumoylated, no 
fibrils appeared. And even if only 10% of the molecules were 
sumoylated, fibril formation slowed dramatically.
SUMO molecules typically attach to two sites on 
-synuclein, the researchers found. Compared with controls, 
cells that produced -synuclein mutants lacking these two 
sites contained more protein clusters and were more likely to 
die by apoptosis. The scientists then genetically altered rats to 
manufacture the -synuclein mutants specifi  cally in neurons. 
Cell death surged in the substantia nigra, the brain region where 
large numbers of neurons perish in PD patients. But whether 
sumoylation goes awry in these patients remains unknown.
Krumova, P., et al. 2011. J. Cell Biol. doi:10.1083/jcb.201010117.
Unsumoylated -synuclein 
aggregates into fibrils (right), 
whereas sumoylated -synuclein 
doesn’t (left).